I Suggest - Cancer

Although prostate cancer is one of the commonest forms of cancer in men, and is currently responsible for the deaths of over 30,000 men every year in th

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

e United States alone, a reluctance on the part of many men to visit their doctor and to talk about anything to do with sex or their sexual organs has m

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

eant that, until recently, prostate cancer has been given something of a low profile.

Today, however, the deaths in the past few years of a number of w

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

ell known personalities from prostate cancer, such as Don Ameche, Telly Savalas and Frank Zappa and the willingness of others, like General Norman Schwa

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

rzkopf, to openly talk about their fight against the disease has done much to raise the profile of prostate cancer and thus to increase prostate cancer

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

research dramatically.

Today a great deal of prostate cancer research is being carried out into the causes, prevention and treatment of the disease and

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

the results of this research, combined with greater public awareness, are being seen as the annual death rate is slowly beginning to fall.

Unfortunate

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

ly far too many cases of prostate cancer are still not being detected until the disease is well established and has often started to spread into surroun

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ding tissue, bone and into the lymphatic system. At this point a common form of treatment is hormone therapy designed principally to slow the spread of

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

the disease, improve the patient's quality of life and increase his survival time. While hormone treatment is effective to some degree it is felt that m

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

ch more can be done in this area and so a great deal of current prostate cancer research is aimed at drug treatment with a number of drugs currently und

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

er test and development.

Prostate cancer research is also being focused particularly on the early diagnosis of the disease, as treatment is relatively

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

simple and extremely effective if prostate cancer is caught early and is still confined to the outer layer of the prostate gland.

One of the standard d

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

iagnostic tests being used today is the PSA test which looks for the presence of a protein within the bloodstream and determines the health of the prost

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ate gland based upon the blood concentration of this protein.

The PSA is a far from a perfect test at this point and there is considerable debate about

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

just how useful it is and when, and in what circumstances, it should be used. In particular, there is a great deal of disagreement about its use as a s

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

creening tool.

A number of leading researcher are focusing their attention on the problems of screening and on the PSA test in particular and progress

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

being made by institutions such as the John Hopkins University Medical School are especially encouraging.

While public awareness is an extremely import

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ant factor in combating prostate cancer, the reduction in the number of deaths from this disease will only to be seen as long as prostate cancer researc

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

h continues and better and faster ways are found to detect the disease at an early stage in its development so that it can be treated with relative ease

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.isuggest.org.ua/article/390583/isuggest-The-Current-State-Of-Prostate-Cancer-Research.html">The Current State Of Prostate Cancer Research</a>

BB link (for phorums):
[url=http://www.isuggest.org.ua/article/390583/isuggest-The-Current-State-Of-Prostate-Cancer-Research.html]The Current State Of Prostate Cancer Research[/url]

Project managers and those associated with projects typically like to measure things. You use words like tons-per-day; cubic-feet-per-minute; megabits-per-second; and so on. Here is a new one for you. Would you be interested in knowing the team building success potential index (TSPI) of your next project? If so, here is a non-scientific, but very pragmatic, way to predict it.

Up until a few years ago, work from home opportunities were rare and poorly paid. This type of work from home slavery still exists but technology has caused a dramatic increase in the number of genuine work from home opportunities available, both for the home based business entrepreneur and for the stay at home mom who wants a job she can fit in around the kids' schedule.

Contrary to what many people believe, a weak and failing heart is not an inevitable part of aging. With proper care, the human heart is good for 100+ years of service. By following these simple, proven, protective measures, you can lower your risk of heart disease to that of a 20-year-old. Your heart is a very forgiving organ and can be rejuvenated. Here's how.

Tags

Links

I Suggest - The Current State Of Prostate Cancer Research

Related Articles: